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Editorial
1Consultant Rheumatologist, Norfolk and Norwich University Hospital, UK
Hydroxychloroquine sulfate (C18H28ClN3O5S) (HCQ) and 
sontoquine C (C19H28ClN3) were amongst the synthetic 
antimalarials created in the 1940s in response to a 
shortage created by the unavailability of mepacrine from 
Germany due to the outbreak of the Second World War.1,2 
The fi rst published report of its use as an antimalarial was in 
1952.3 It was fi rst used in 1956 for managing discoid lupus 
(DLE)4,5 and systemic lupus erythematosus.6 The United 
States’ Food and Drug Administration approved its use for 
DLE in 1958. By 1960 Plasmodium resistance to HCQ was 
already being recognised.7 But other indications were being 
discovered for its use viz. amoebiasis,8 rheumatoid arthritis,9 
porphyria cutanea tarda10 and Sjogren’s syndrome.11 That we 
understand the mechanism of action of this drug in any of its 
indications would be a vast overstatement. There is some 
evidence that it reduces the leucocyte motility,12 may reduce 
antibody production, interfere with interleukin-1 production 
from monocytes,13 and produce lysosomal dysfunction.14
Coronaviruses are enveloped positive-sense single-stranded 
RNA viruses belonging to the order Nidovirales, family 
Coronaviridae. Distinct viruses causing an infective bronchitis 
had been known about since the fi rst half of the twentieth 
century.15 Their typical electron microscopic appearance 
resembling the solar corona was recognised in the late 
1960s.16 At around the same time, it was also recognised 
that these hitherto zoonotic viruses could also affect humans 
causing respiratory symptoms like the common cold.17 Within 
the coronavirus subfamily is the genus Betacoronavirus, 
members of which have been responsible for causing large-
scale outbreaks in humans: the Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory 
Syndrome Coronavirus (SARS-CoV) and the current pandemic 
with SARS-CoV-2.
HCQ has previously been considered as an adjunctive 
treatment in the management of RNA viruses because of 
its in vitro ability to reduce post-transcriptional modifi cation 
and bolster the host defence mechanisms.18,19 A randomised 
double-blind placebo-controlled trial of HCQ 800 mg/day in 
patients with asymptomatic Human Immunodefi ciency Virus 
(HIV)-1 infection, confi rmed this fi nding.20 In these patients, it 
even appeared to have greater ability to suppress interleukin-6 
and immunoglobulin G levels compared with zidovudine.21 It 
was thought to be a good adjunctive drug for treating HIV-1 
infection in countries where the newer expensive antiretroviral 
drugs were not affordable,22 but this fell out of favour because 
of its ineffi cacy in individuals with a high viral load. It has 
been shown to be of value in conjunction with Interferon-α 
and ribavirin for hepatitis C.23
For SARS-CoV-2, in vitro physiologically based pharmacokinetic 
modelling suggests that HCQ 400 mg bd as a loading dose 
followed by 200 mg twice daily for four days may be an 
effective treatment.24 A similar regimen (the loading dose 
was 600 mg bd) was used in patients admitted to a New 
York hospital.25 This retrospective observational study of 
1,376 patients admitted with SARS-CoV-2 was designed to 
look at the role of HCQ in reducing time to intubation or 
death (whichever was earlier), but stopped short of giving 
us that information. However, the study did report that in 
patients treated with HCQ, there was no benefi t in preventing 
intubation or death on multivariate analysis (hazard ratio 1.0) 
(Table 1). They conducted a further analysis after propensity 
matching the HCQ-naïve cohort with the same result. In two 
further peer-reviewed studies from Marseille (with some case 
overlap) they used a different dose26,27 (Table 1). They found a 
signal for increased virological clearance on day 6 in patients 














Keywords: hydroxychloroquine, RNA viruses, SARS-CoV-2, antimalarial drugs, clinical 
pharmacology, zoonotic diseases, pandemic
Financial and Competing Interests: No confl icts of interest declared
Hydroxychloroquine and coronavirus 
disease 2019
Chetan Mukhtyar1
102    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH  VOLUME 50  ISSUE 2  JUNE 2020
biases with the control arm consisting of patients who had 
refused treatment or were not offered it. The second larger 
uncontrolled observational study (n=80) did not analyse for 
their primary outcome of requirement for oxygen therapy or 
transfer to intensive care. Only 15% of the patients in that 
study required oxygen at any time, calling into question the 
need for hospital admission for the other 85%.
In a retrospective study of a large healthcare database 
from Israel (n=14,520), the 1,317 individuals that tested 
positive for SARS-CoV-2 were compared to those who were 
not suspected to have the infection. 0.23% of the positive 
sample were HCQ users, compared with 0.25% of the control 
group. They concluded that HCQ use was not associated with 
any prophylactic benefi t in preventing the infection.28 
In 2017, 2018 and 2019 there were 336, 401 and 432 
publications respectively addressing some aspect of HCQ 
(data from PubMed). In 2020, there have already been 
401 articles on HCQ (data from PubMed, 9 May 2020). 
Of that vast quantity of medical literature, there is not one 
randomised placebo-controlled trial, but the dearth of data 
has been fi lled by opinion, biased studies and speculation. 
There is an opinion that we should ‘think outside the box’ 
and why shouldn’t we try a drug when people are dying? The 
practice of medicine is guided by the principle primum non 
nocere (fi rst do no harm), not primum aliquid attentent (fi rst 
try something). Rheumatologists will attest that HCQ is a safe 
drug, but it is a mistake to assume that it is not capable of 
producing highly toxic adverse effects.29 Its effect on cardiac 
conduction pathways, ocular toxicity and agranulocytosis have 
been recognised since the 1960s.30-32 There appears to be 
a wide difference in blood concentrations of the drug33 and 
in some individuals even small doses of the drug have been 
implicated in behavioural changes leading to accidental or 
intentional overdose and death.34 In the absence of defi nitive 
evidence of effi cacy, it would be medically negligent to offer 
a treatment with an adverse risk-benefi t ratio. These are 
extraordinary times, and it is in these times that it is most 
important to keep our heads and use sound principles of 
medical practice. 
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in the active centre or 
were enrolled at centres 











HCQ 200 mg tds 
for 10 days + AZI 
500 mg on day 
1, 250 mg on 
day 2–5 + CEF 
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transfer to ICU on 
day 3
No information The paper comments 
that 15% of patients 
required oxygen during 
their inpatient stay. 
There is no information 
on numbers needing 
oxygen on day 0 and 
day 3
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There are no data on 
time to intubation or 
death between the 
intervention and control 
arms. However, there 
is information about 
number of events.
262/811 (32.3%) of 
patients in Intervention 
arm had an event; 
84/565 (14.9%) of 
patients in Control arm 
had an event
PCR: polymerase chain reaction; AZI: azithromycin; CEF: ceftriaxone; ICU: intensive care unit
Table 1 The characteristics of three studies of HCQ in SARS-CoV-2
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